Which findings would the nurse interpret as a nonacceptable response to DMARDs therapy?

In the context of Disease-Modifying Antirheumatic Drugs (DMARDs) therapy, a response characterized by increased pain in joints would be seen as nonacceptable. DMARDs are designed to reduce inflammation, inhibit disease progression, and ultimately alleviate symptoms associated with autoimmune conditions such as rheumatoid arthritis.

An increase in joint pain suggests that the DMARDs are not effectively managing the patient's condition, indicating potential treatment failure or the need for adjustment in dosage or medication type. This serves as a signal for healthcare providers to reassess the treatment plan, as an effective response to DMARDs should ideally lead to a decrease in symptoms, including pain and stiffness.

In contrast, normal blood cell counts, radiological nonprogression, and increased range of motion are indicators of positive therapeutic effects of DMARDs. They suggest that the treatment is successfully minimizing the disease's impact on the body, reducing joint damage, and enhancing functional ability.